CardioMetabolics receives $4.1 million in financing

CardioMetabolics Inc has secured $4.1 million in a private equity financing to advance its work on drug candidates for cardiovascular disease and related metabolic conditions. Canaccord Capital Corp led the financing of the Edmonton-based, privately held firm. CardioMetabolics' initial target for its lead drug candidate is to improve outcomes and recovery times for patients who have had open heart surgery…